Medical Equipment & Supplies

Products- Disposables and consumables (syringes, catheters, sutures, IV sets), implants (stents, orthopaedic), diagnostic imaging equipment, surgical instruments

Export-grade consumables: A few scaled Indian manufacturers have built volume-led catheter and IV cannula businesses with genuine global reach and regulatory approvals

Domestic value-add in disposables: Where products are made rather than assembled, local content is high and the economics resemble branded manufacturing rather than import repackaging

MNC dominance in high-end equipment: MRI and CT are controlled by global majors, with critical components such as X-ray tubes and detectors still imported even at domestic assembly plants, capping local value-add at ~40-50%

Single-category concentration: Several manufacturers depend on one product line for over half of revenue, leaving them exposed to demand or pricing shifts in that single category

Customers- Hospitals (~65% of demand), diagnostic centres, government tenders, distributors

Hospital capex cycle: The current hospital bed-addition programme creates a multi-year equipment and consumables demand stream tied to committed capital plans

Institutional buyer power: Hospitals and government tenders are large, price-sensitive buyers with strong bargaining power on commodity disposables

Import dependence on inputs: Reliance on imported devices and components at ~70-86% exposes manufacturers to global supply and currency risk they cannot hedge operationally

Tender-driven pricing: Government procurement is awarded on lowest cost among qualified bidders, so approval status rather than product merit determines who competes

Cost structure- Raw materials and imported components run ~45-55% for import-heavy device categories, but well-run domestic consumables makers operate closer to ~33-35%

Value-add shows in margin: The gap between those two ranges reflects genuine domestic manufacturing rather than assembly, and translates into EBITDA margins of ~27% for the best-run names, closer to branded pharma than commodity manufacturing

Volume economics in disposables: Lower capex per unit of output and high throughput make consumables genuinely scalable once approvals are in place

Employee cost volatility: Staff costs are a smaller share at ~18% but can step up sharply with new-plant commissioning or compliance hiring, driving material EBITDA swings within a single quarter

Tax & duty drag: GST of 12-18% plus a 5% health cess, and an inverted duty structure taxing imported components above finished goods, add cost pressure domestic manufacturers cannot pass on

Market- ~$14-19bn currently, targeted at ~$50bn by 2030 (third-party CAGR estimates range widely, ~6-16%)

Govt. programs: The PLI scheme (Rs 3,420cr outlay, FY23-27) has commissioned 22 greenfield projects delivering ~Rs 12,344cr cumulative sales and ~Rs 5,869cr exports by September 2025, covering MRI/CT, dialysers, heart valves and other import-heavy categories

Enabling infrastructure: 100% FDI is permitted and four medical device parks are operationalising shared testing and sterilisation infrastructure that individual SMEs could not fund

Domestic healthcare demand: Rising chronic-disease burden, the hospital capex cycle and medical value travel together lift domestic device consumption independent of exports

Export momentum: Device exports grew ~88% to around $3.6bn in FY25 as Indian consumables gained regulatory approvals in new markets

Post-incentive uncertainty: The PLI window closes in FY26-27 and value-addition for many nominally domestic devices remains limited since critical components are still imported, leaving post-PLI cost competitiveness untested

Structure- Import-dominated in high-end categories, with domestic manufacturers holding real share only where capex is lower

Consumables stronghold: Domestic players hold genuine share in disposables and consumables, where lower capital intensity and volume support scale economics

Regulatory approvals as barrier: CDSCO licensing and export-market registrations take years, protecting established manufacturers against quick entry

Inverted duty structure: Imported finished goods are taxed below imported components, directly undermining domestic cost competitiveness against imports

Compliance burden on SMEs: High surveillance and quality-system costs strain smaller manufacturers far more than large players or multinational subsidiaries

Principal risks are price control, import dependence, incentive expiry and structural duty disadvantages

Regulatory price caps: NPPA cuts to stent and knee-implant prices of up to 65-85% compress manufacturer margins directly, not only hospital margins

Import & currency exposure: Dependence on imported devices and components at 70-86% exposes manufacturers to supply shocks and rupee movement

Incentive taper: PLI benefits taper from FY26-27 while long gestation and high R&D costs continue to strain smaller firms

Structural duty disadvantage: The inverted duty structure and multi-layered GST and cess leave domestic production at a cost disadvantage relative to finished imports

Localisation momentum: Device parks, shared test infrastructure and rising export approvals are progressively deepening the domestic component base, which over time reduces the import exposure that defines the segment's current risk profile